KDR and hepatocellular carcinoma: Lenvatinib, a multikinase inhibitor of the VEGFR family of protein, fibroblast growth factor receptor, PDGFR-α, and KIT and RET inhibitors, was the second approved first-line targeted drug for advanced HCC.